Gilda Rossoni

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

Vanesa Gregorc, Paolo Andrea Zucali, Armando Santoro et al. · Journal of Clinical Oncology · 2010 · 109 citations · Full text

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Vanesa Gregorc, Filippo de Braud, Tommaso Martino De Pas et al. · Clinical Cancer Research · 2011 · 54 citations

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

Vanesa Gregorc, Giovanni Citterio, Giordano Vitali et al. · European Journal of Cancer · 2009 · 52 citations

Optimal Biological Dose, Oncology, Selective Vascular +10

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

Alessandra Bearz, Renato Talamini, Gilda Rossoni et al. · BMC Research Notes · 2012 · 45 citations · Full text

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

Armando Santoro, Tiziana Pressiani, Giovanni Citterio et al. · British Journal of Cancer · 2010 · 30 citations · Full text